The effects of losartan or angiotensin II receptor antagonists on cartilage: a systematic review

• Published in: Osteoarthritis and cartilage Vol. 31; no. 4; pp. 435 - 446
• Main Authors: Yamaura, K., Nelson, A.L., Nishimura, H., Rutledge, J.C., Ravuri, S.K., Bahney, C., Philippon, M.J., Huard, J.
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.04.2023
• Subjects: Angiotensin; Angiotensin II Type 2 Receptor Blockers; Angiotensin Receptor Antagonists; Animals; Cartilage; Humans; Losartan; Losartan - pharmacology; Losartan - therapeutic use; Osteoarthritis; TGF-β1; Cartilage; TGF-β1; Osteoarthritis; Losartan; Angiotensin
• ISSN: 1063-4584; 1522-9653
• DOI: 10.1016/j.joca.2022.11.014

The aim of this study is to analyze the latest evidence on the effects of losartan or Ang II receptor antagonists on cartilage repair, with a focus on their clinical relevance. The PubMed, Embase, and Cochrane Library databases were searched up to November 12th 2021 to evaluate the effects of losartan or Ang II receptor antagonists on cartilage repair in in vitro studies and in vivo animal studies. Study design, sample characteristics, treatment type, duration, and outcomes were analyzed. The risk of bias and the quality of the eligible studies were assessed using the Systematic Review Centre for Laboratory Animal Experimentation (SYRCLE) risk of bias assessment tool and Collaborative Approach to Meta-Analysis and Review of Animal Data from Experimental Studies (CAMARADES). A total of 12 studies were included in this systematic review. Of the 12 eligible studies, two studies were in vitro human studies, three studies were in vitro animal studies, one study was an in vitro human and animal study, and six studies were in vivo animal studies. The risk bias and quality assessments were predominantly classified as moderate. Since meta-analysis was difficult due to differences in treatment type, dosage, route of administration, and method of outcome assessment among the eligible studies, qualitative evaluation was conducted for each study. Both in vitro and in vivo studies provide evidence to demonstrate beneficial effects of Ang II receptor antagonists on osteoarthritis and cartilage defect models across animal species.